• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

钙调磷酸酶抑制剂的肾毒性是肾移植后 BK 多瘤病毒复制的一个危险因素。

Nephrotoxicity of calcineurin inhibitors as a risk factor for BK polyomavirus replication after kidney transplantation.

机构信息

Department of Internal Medicine III - Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, University Hospital, Palacký University Olomouc, Olomouc, Czech Republic.

Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, University Hospital, Palacký University Olomouc, Olomouc, Czech Republic.

出版信息

J Med Virol. 2021 Jun;93(6):3871-3879. doi: 10.1002/jmv.26520. Epub 2020 Oct 7.

DOI:10.1002/jmv.26520
PMID:32940913
Abstract

BK polyomavirus-associated nephropathy (PyVAN) is responsible for a significant percentage of transplanted kidneys prematurely terminating their function. Its occurrence is closely related to the intensity of immunosuppressive therapy. In a group of 161 newly transplanted patients, we prospectively evaluated 457 protocol renal biopsies performed within the first year after transplantation. Using the calcineurin inhibitors (CI) nephrotoxicity score, the incidence of nephrotoxicity was monitored as a manifestation of excessive immunosuppression. Findings were correlated with clinical evidence of active BK polyomavirus (BKPyV) replication and PyVAN. Compared to the normal histology, nephrotoxicity was associated with more frequent BKPyV viremia and viruria (p = .01 and p < .01, respectively) and more common occurrence of PyVAN. The persistence of toxicity in the subsequent biopsy proved to be a negative risk factor of viremia and viruria (p = .03 and p < .01, respectively), independently of the initial BKPyV status. Toxicity could also be used as a predictor of viremia and viruria (p = .04 and p < .01, respectively) even in the absence of viral replication at the time of initial biopsy. The early histological manifestation of CI nephrotoxicity was associated with significant BKPyV reactivation in the risky first posttransplant year.

摘要

BK 多瘤病毒相关性肾病 (PyVAN) 可导致相当一部分移植肾脏提前丧失功能,其发生与免疫抑制治疗的强度密切相关。在 161 名新移植患者中,我们前瞻性评估了移植后 1 年内进行的 457 次协议性肾活检。采用钙调磷酸酶抑制剂 (CI) 肾毒性评分监测肾毒性作为过度免疫抑制的表现。将结果与 BK 多瘤病毒 (BKPyV) 复制和 PyVAN 的临床证据相关联。与正常组织学相比,肾毒性与更频繁的 BKPyV 血症和尿病毒载量(p =.01 和 p <.01)以及更常见的 PyVAN 相关。随后活检中持续存在毒性被证明是病毒血症和尿病毒载量的负面风险因素(p =.03 和 p <.01),与初始 BKPyV 状态无关。即使在初始活检时没有病毒复制,毒性也可用作病毒血症和尿病毒载量的预测因素(p =.04 和 p <.01)。CI 肾毒性的早期组织学表现与移植后风险较高的第一年中 BKPyV 的显著再激活相关。

相似文献

1
Nephrotoxicity of calcineurin inhibitors as a risk factor for BK polyomavirus replication after kidney transplantation.钙调磷酸酶抑制剂的肾毒性是肾移植后 BK 多瘤病毒复制的一个危险因素。
J Med Virol. 2021 Jun;93(6):3871-3879. doi: 10.1002/jmv.26520. Epub 2020 Oct 7.
2
Stabilization of renal function after the first year of follow-up in kidney transplant recipients treated for significant BK polyomavirus infection or BK polyomavirus-associated nephropathy.肾移植受者在接受显著BK多瘤病毒感染或BK多瘤病毒相关性肾病治疗后的第一年随访期后肾功能的稳定情况。
Transpl Infect Dis. 2017 Jun;19(3). doi: 10.1111/tid.12681. Epub 2017 Apr 17.
3
Impact of donor BK polyomavirus replication on recipient infections in living donor transplantation.供体BK多瘤病毒复制对活体供体移植中受体感染的影响。
Transpl Infect Dis. 2018 Aug;20(4):e12917. doi: 10.1111/tid.12917. Epub 2018 Jun 11.
4
Determination of viremia cut-off for risk to develop BKPyV-associated nephropathy among kidney transplant recipients.确定肾移植受者发生BK多瘤病毒相关性肾病风险的病毒血症临界值。
Transpl Infect Dis. 2018 Oct;20(5):e12969. doi: 10.1111/tid.12969. Epub 2018 Sep 3.
5
The detection of BKPyV genotypes II and IV after renal transplantation as a simple tool for risk assessment for PyVAN and transplant outcome already at early stages of BKPyV reactivation.肾移植后检测 BKPyV 基因型 II 和 IV 可作为一种简单的工具,用于在 BKPyV 再激活的早期阶段评估 PyVAN 风险和移植结果。
J Clin Virol. 2019 Apr;113:14-19. doi: 10.1016/j.jcv.2019.02.002. Epub 2019 Feb 10.
6
The status of BK polyomavirus replication in adult renal transplant recipients in northeastern Poland.波兰东北部成年肾移植受者中BK多瘤病毒复制的状况。
Transplant Proc. 2011 Oct;43(8):2976-84. doi: 10.1016/j.transproceed.2011.07.009.
7
Prevalence of polyoma BK virus infection among living-donor renal transplant recipients.活体供肾肾移植受者中多瘤BK病毒感染的患病率。
Transpl Infect Dis. 2016 Aug;18(4):529-37. doi: 10.1111/tid.12557. Epub 2016 Jul 29.
8
Impact of HMG-CoA reductase inhibitors on the incidence of polyomavirus-associated nephropathy in renal transplant recipients with human BK polyomavirus viremia.HMG-CoA还原酶抑制剂对感染人BK多瘤病毒且发生病毒血症的肾移植受者中多瘤病毒相关性肾病发病率的影响。
Transpl Infect Dis. 2015 Aug;17(4):536-43. doi: 10.1111/tid.12402. Epub 2015 Jun 26.
9
Early fulminant BK polyomavirus-associated nephropathy in two kidney transplant patients with low neutralizing antibody titers receiving allografts from the same donor.两名接受同一供体同种异体移植物的肾移植患者,由于低中和抗体滴度而发生早期暴发性 BK 多瘤病毒相关性肾病。
Virol J. 2020 Jan 10;17(1):5. doi: 10.1186/s12985-019-1275-9.
10
Prospective monitoring of BK virus replication in renal transplant recipients.肾移植受者中BK病毒复制的前瞻性监测。
Transpl Infect Dis. 2009 Feb;11(1):1-10. doi: 10.1111/j.1399-3062.2008.00342.x. Epub 2008 Sep 21.